SIAH1 KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 2 bp deletion in exon 2 and 4 bp deletion in exon 2. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
대체 명칭 보기
SIAH1, RING-type E3 ubiquitin transferase SIAH1, Seven in absentia homolog 1, Siah-1a, E3 ubiquitin-protein ligase SIAH1, HUMSIAH, Siah-1
- Sanger seq
Unknown
Sanger Sequencing - Human SIAH1 knockout HeLa cell line (AB264746)
Allele-2 : 2 bp deletion in exon 2.
- Sanger seq
Unknown
Sanger Sequencing - Human SIAH1 knockout HeLa cell line (AB264746)
Allele-1 : 4 bp deletion in exon 2.
제품 세부 정보
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.
제품 구성
특성 및 보관 정보
유전자명
유전자 편집 종류
유전자 편집 방식
Knockout 검증
배송 시 보관 조건
적절한 단기 보관 조건
적절한 장기 보관 조건
추가 정보
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
SIAH1 influences cell cycle control and apoptosis by interacting with components of protein complexes. It associates with the ubiquitin-proteasome pathway to mediate degradation of key regulatory proteins. SIAH1 helps in reducing cellular proliferation and enhances apoptotic signaling which are vital processes for maintaining balance between cell survival and death. As part of these processes studies have connected SIAH1 to modulating the fate of proteins involved in cell cycle arrest.
Pathways
Several interactions of SIAH1 contribute to signal transduction and apoptosis. One significant pathway involving SIAH1 is the p53 signaling pathway. SIAH1 regulates the degradation of proteins within this pathway including p21 and cyclin D1 which influence cellular responses to DNA damage. Additionally SIAH1 interacts with β-catenin linking it to the Wnt signaling pathway. This interaction affects the regulation of cell growth and differentiation.
품질 관리
STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
Biosafety level
EU: 2 US: 2
Adherent/suspension
Adherent
Gender
Female
초기 취급 지침
Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability. <p>1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.<br>2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.<br>3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.<br>4. Incubate the culture at 37°C incubator with 5% CO<sub>2</sub>. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.<br>5. Once confluent passage into an appropriate flask at a density of 2x10<sup>4</sup> cells/cm<sup>2</sup>. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.</p>
Subculture 가이드라인
- All seeding densities should be based on cell counts gained by established methods.
- A guide seeding density of 2x104 cells/cm2 is recommended.
- Cells should be passaged when they have achieved 80-90% confluence.
배양 배지
DMEM (High Glucose) + 10% FBS
동결보존 배지
Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com